Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSES / FLOT7
2015-003118-26Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of ramucirumab in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophagogastric junction cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Rate of pathological complete or subtotal responses (pCR/pSR). Started Feb 2016; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on 2015-003118-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003118-26.